Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

Erik Bjørnager Dam; Marco Loog; Claus Christiansen; Inger Byrjalsen; Jenny Maria Folkesson; Mads Nielsen; Arish Asif Qazi; Paola Pettersen; Patrick Garnero; Morten A Karsdal

doi:10.1186/ar2774

Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

Erik Bjørnager Dam, Marco Loog, Claus Christiansen, Inger Byrjalsen, Jenny Maria Folkesson, Mads Nielsen, Arish Asif Qazi, Paola Pettersen, Patrick Garnero, Morten A Karsdal

Datalogisk Institut

87 Citationer (Scopus)

Abstract

At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.

Originalsprog	Engelsk
Tidsskrift	Arthritis Research & Therapy
Vol/bind	11
Udgave nummer	4
Sider (fra-til)	1-11
ISSN	1478-6362
DOI	https://doi.org/10.1186/ar2774
Status	Udgivet - 24 jul. 2009

Adgang til dokumentet

10.1186/ar2774

http://arthritis-research.com/content/11/4/R115

Citationsformater

@article{dc844410260211df8ed1000ea68e967b,

title = "Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.",

abstract = "At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.",

author = "Dam, {Erik Bj{\o}rnager} and Marco Loog and Claus Christiansen and Inger Byrjalsen and Folkesson, {Jenny Maria} and Mads Nielsen and Qazi, {Arish Asif} and Paola Pettersen and Patrick Garnero and Karsdal, {Morten A}",

year = "2009",

month = jul,

day = "24",

doi = "10.1186/ar2774",

language = "English",

volume = "11",

pages = "1--11",

journal = "Arthritis Research & Therapy",

issn = "1478-6362",

publisher = "BioMed Central",

number = "4",

}

TY - JOUR

T1 - Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

AU - Dam, Erik Bjørnager

AU - Loog, Marco

AU - Christiansen, Claus

AU - Byrjalsen, Inger

AU - Folkesson, Jenny Maria

AU - Nielsen, Mads

AU - Qazi, Arish Asif

AU - Pettersen, Paola

AU - Garnero, Patrick

AU - Karsdal, Morten A

PY - 2009/7/24

Y1 - 2009/7/24

N2 - At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.

AB - At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.

U2 - 10.1186/ar2774

DO - 10.1186/ar2774

M3 - Journal article

C2 - 19630944

SN - 1478-6362

VL - 11

SP - 1

EP - 11

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

IS - 4

ER -

Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater